Prime Medicine, Inc.
PRME · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,225 | $1,115 | $1,454 | $2,183 |
| % Growth | 9.9% | -23.3% | -33.4% | – |
| Cost of Goods Sold | $43,990 | $1,864 | $0 | $0 |
| Gross Profit | -$42,765 | -$749 | $1,454 | $2,183 |
| % Margin | -3,491% | -67.2% | 100% | 100% |
| R&D Expenses | $43,990 | $41,375 | $40,562 | $34,104 |
| G&A Expenses | $11,208 | $13,117 | $13,284 | $12,301 |
| SG&A Expenses | $11,208 | $13,117 | $13,284 | $12,301 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$43,990 | -$1,864 | $0 | $0 |
| Operating Expenses | $11,208 | $52,628 | $53,846 | $46,405 |
| Operating Income | -$53,973 | -$53,377 | -$52,392 | -$44,222 |
| % Margin | -4,406% | -4,787.2% | -3,603.3% | -2,025.7% |
| Other Income/Exp. Net | $3,391 | $786 | $502 | $1,946 |
| Pre-Tax Income | -$50,582 | -$52,591 | -$51,890 | -$42,276 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$50,582 | -$52,591 | -$51,890 | -$42,276 |
| % Margin | -4,129.1% | -4,716.7% | -3,568.8% | -1,936.6% |
| EPS | -0.32 | -0.407 | -0.397 | -0.357 |
| % Growth | 21.4% | -2.7% | -11.2% | – |
| EPS Diluted | -0.32 | -0.407 | -0.397 | -0.357 |
| Weighted Avg Shares Out | 160,503 | 129,186 | 130,884 | 118,600 |
| Weighted Avg Shares Out Dil | 160,503 | 129,186 | 130,884 | 118,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,141 | $1,273 | $1,182 | $1,538 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,881 | $1,864 | $1,700 | $1,717 |
| EBITDA | -$48,701 | -$51,513 | -$50,692 | -$42,505 |
| % Margin | -3,975.6% | -4,620% | -3,486.4% | -1,947.1% |